Biomarker Market 2020-2026
在預測期內，全球生物標誌物市場預計將以 14.6% 的複合年增長率增長。生物標誌物是對特定時刻細胞或生物體中發生的事情的客觀測量。生物標誌物充當健康的早期預警系統。生物標誌物可以具有分子、組織學、放射學或生理學特性。生物標誌物在基礎研究和臨床研究以及臨床實踐中的使用已經變得非常普遍，現在幾乎毫無疑問地接受了生物標誌物作為臨床試驗主要終點的存在。
促進全球生物標誌物市場增長的主要因素是慢性病的高患病率、生物標誌物在診斷應用中的採用增加以及政府對癌症研究和臨床試驗的高額資助。包括藥物發現和開發中的使用增加。根據美國國家慢性病預防和健康促進中心 (NCCDPHP) 的一份報告，美國每 10 個成年人中就有 6 個至少患有一種慢性病，而每 10 個成年人中就有 4 個患有一種以上的慢性病。到 2060 年，美國 65 歲及以上人口估計將從目前的 4600 萬增加到 9800 萬。慢性病的高患病率導致對有效生物標誌物的需求，這反過來又進一步推動了市場增長。合同研究組織（CRO）數量的增加和新興市場臨床試驗的低成本預計將進一步推動市場增長。
根據疾病，癌症生物標誌物預計將在 2020 年佔據市場主導地位，並在預測期間保持這種主導地位。由於全球癌症患病率不斷上升，近年來對癌症生物標誌物的需求顯著增加，對市場增長產生了積極影響。國際癌症研究機構 (IARC) 估計，2018 年全球有 1700 萬新癌症病例和 950 萬癌症死亡。到 2040 年，僅由於人口增長和老齡化，全球負擔預計將增加到 2750 萬新癌症病例和 1630 萬癌症死亡。根據世界衛生組織 2020 年的癌症數據，癌症是全球主要的死亡原因。因肺癌（180萬）、結腸直腸癌（93.5萬）、肝癌（83萬）、胃癌（76.9萬）、乳腺癌（68.5萬）等各種癌症導致1000萬人死亡。在癌症研究和藥物發現中，生物標誌物具有診斷（支持早期診斷病情）、預後（用於預測病情進展）和預測（用於預測治療後的反應）。它以三種方式使用.預計癌症患病率的增加將增加生物標誌物在研究相關活動中的使用，並進一步推動市場增長。
從地理位置來看，預計北美將在 2020 年佔據主要市場份額，並在預測期內主導市場。對市場做出貢獻的主要經濟體是美國和加拿大。對市場增長有顯著貢獻的因素包括發達的醫療保健基礎設施、醫療保健研發投資的增加以及高昂的醫療保健成本。越來越多的癌症患者被認為是推動北美市場增長的關鍵驅動因素之一。美國的醫療保健成本比率高於加拿大，因為美國政府正在加大對研發的投資。此外，健康、收入和人口基數等社會經濟因素在美國創造的商機比在加拿大多。
生物標誌物市場的主要參與者通過提供種類繁多的產品並擴大其在全球的地理分佈做出了重大貢獻。市場上的主要參與者是，除其他外Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc.。為了在市場中生存，這些市場參與者採用了多種營銷策略，例如併購、研發、產品發佈和地域擴張。例如，2020 年 12 月，Personalis, Inc. 宣佈推出自己的新抗原呈現評分 (NEOPS)。它是一種新的基於抗原的複雜生物標誌物，用於癌症免疫治療反應。 NEOPS 結合 Personalalis、Next Platform 腫瘤基因組和免疫相關分析，創建複雜的生物標誌物，可以更有效地預測免疫治療反應。
Global Biomarker Market Size, Share & Trends Analysis Report by Type (Genomic Biomarker, and Protein Biomarker) By Application (Drug Discovery & Development, Diagnostic, Prognostic, Predictive, and Others ) By Disease (Cancer, Cardiac, Renal, Central Nervous System Disease, and Others) By End-User (Hospitals, Diagnostic Centre, and Research Institute) Forecast 2021-2027
The global market for a biomarker is projected to have a CAGR of 14.6% during the forecast period. A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. Biomarkers can have molecular, histologic, radiographic, or physiological characteristics. The use of biomarkers in basic and clinical research as well as in clinical practice has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question. The key factors contributing to the growth of the global biomarker market include the high prevalence of chronic diseases, rising adoption of the biomarker for diagnostic applications, high government funding for cancer research and clinical trials, increasing application in drug discovery and development. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) report, 6 in 10 adults in America live with at least one chronic disease, and 4 in 10 adults are with two or more. It is estimated that by 2060, the U.S. population aged 65 years and older will more than double, from 46 million today to 98 million. The high prevalence of chronic disease led to the demand for an effective biomarker which, in turn, further drive the market growth. The increase in the number of Contract Research Organizations (CROs) and the low cost of clinical trials in emerging economies are anticipated to further boost the growth of the market.
However, the high investments cost and low-cost benefit ratio and technical issues such as sample collection and storage are restraining the growth of the biomarker market. The increasing government initiatives for R&D, the introduction of new technologies such as digital biomarker and rising adoption in personalized medicine are expected to create lucrative opportunities for the market.
The global biomarker market is segmented based on type, application, disease, and end-user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is classified into drug discovery & development, diagnostic, prognostic, predictive and others (risk assessment). Among these, the biomarkers in drug discovery and development are anticipated to grow at significant CAGR during the forecast period. Biomarkers can predict the drug efficacy more quickly than conventional clinical endpoints, also they have the potential to accelerate product development in certain disease areas such as cancer, and cardiac disease. The disease segment is segregated into cancer, cardiac, renal, central nervous system disease and others (NASH). The end-user segment is categorized into hospitals, diagnostic center and research institute.
Global Biomarker Market Share by Disease, 2020 (%)
Source: OMR global
The Cancer disease segment holds the Major Market Share in the global Biomarker Market.
Among disease, the biomarker in cancer dominated the market in 2020, and it is anticipated to maintain its dominance during the forecast period. Due to rise in prevalence of cancer cases across the globe, the demand for cancer biomarker has increased significantly in recent years, that has positively impacted the market growth. According to estimates from the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and ageing of the population. According to the WHO data for cancer 2020, cancer is the main cause of death across the globe. There were 10 million deaths accounted for due to various types of cancer such as lung (1.80 million), colon and rectum (935 000), liver (8,30,000), stomach (769 000), and breast (685 000 deaths). In cancer research and drug discovery, biomarkers are used in three ways such as diagnostic (support to diagnose the condition in early-stage), prognostic (to forecast how aggressive a condition is), and predictive (to predict the response after treatment). The rising prevalence of cancer disease will increase the use of biomarkers in research-related activities which will further expected to drive the market growth.
Geographically, the global Biomarker market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is the fastest-growing region during the forecast period. The factors contributing to the regional growth include the strong population base, high prevalence of chronic diseases such as cancer and CVDs in countries such as China, Japan, and India. Apart from this, improving biopharmaceutical research centers and rising clinical research in the region.
Global Biomarker Market Growth, by Region 2021-2027
Source: OMR Global
North America is projected to Dominate the Biomarker Market
Geographically, North America held the major market share in 2020, and it is anticipated to dominate the market during the forecast period. Major economies which contribute to the market are the US and Canada. Factors that are contributing significantly to the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the North American region. The healthcare expenditure rate of the US is more than that of Canada, as the US government invests more in R&D. Furthermore, socioeconomic factors such as health, income, population base creates more business opportunity in the US as compared to Canada.
Market Players Outlook
The key players in the biomarker market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc., among others. To survive in the market, these market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on. For instance, in December 2020, Personalis, Inc. announced the launch of proprietary Neoantigen Presentation Score (NEOPS). It is a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines the tumor genomic and immune-related analytics of the Personalis, Next Platform in order to create a composite biomarker through which immunotherapy response can be predicted more effectively.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global biomarker market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.